Maier, A
But semaglutide, a GLP-1 receptor agonist, is in WADA's monitoring program
Jon Mendelsohn says she is hearing stories like Fairs more often as demand continues to grow
The questions are very relevant in this group of patients, because the primary prophylactic treatment strategy was e.g
Sanjeev Sockalingam, Scientific Director, framed the approval as a regulatory milestone that should "prompt governments, insurers, and employers to reconsider how obesity treatment is covered within these systems," noting that "fewer than 20 per cent of Canadians with private drug benefit plans have access to Health Canada-approved obesity treatment medications"
On one hand, these medications can help you manage your blood sugar and lose weight, but on the other hand, they can come with some unpleasant side effects